Background: Asenapine demonstrated superiority over placebo for mania in bipolar I disorder patients experiencing acute current manic or mixed episodes in 2 randomized, placebo-and ...

This medication is an atypical antipsychotic agent, prescribed for schizophrenia and acute mania with bipolar disorder.

Background: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has ...

Review the side-effects of Asenapine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so ...

“Asenapine is a well-established treatment option and delivering it transdermally with SECUADO provides a non-intrusive approach and visual confirmation of adherence,” said Leslie Citrome, M.D., M.P.H ...

Schizophrenia is a difficult condition for patients and their families to manage. Relapse is a frequent occurrence, particularly if patients decide to discontinue antipsychotic drug treatment because ...

Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for ...

Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST® (asenapine) sublingual tablets in all markets outside of the United States, China and Japan Release date: 12-10-2010 SYCREST® ...

Organon, the healthcare business of The Netherlands’s Akzo Nobel, has presented promising late-stage data for its experimental antipsychotic asenapine. Organon, the healthcare business of The ...

AMSTERDAM, Nov 28 (Reuters) - Dutch chemical group Akzo Nobel and Pfizer said on Tuesday they will no longer jointly develop asenapine, a schizophrenia treatment that was expected to bolster Akzo's ...

New Data From a Separate Study Also Show Minimal Effect on Heart Rhythm Changes in Schizophrenia Patients VIENNA, Austria, Oct. 17 -- New data show that asenapine -- a psychopharmacologic agent being ...